Search
Coji Pharmaceutical's CAR-T Therapy Targeting Claudin18.2 Prioritized for Stomach Cancer Review
2025-05-22 /
Read about 0 minute
Author：小编
Coji Pharmaceutical's surulizumab (CT041) represents a groundbreaking autologous CAR-T cell product specifically designed to target the Claudin18.2 protein, which is notably expressed in over half of all stomach and pancreatic cancer cases. This innovative treatment holds promise for patients with advanced gastric/esophagogastric junction adenocarcinoma. In September 2020, CT041 was granted orphan drug status by the U.S. Food and Drug Administration (FDA) for the treatment of gastric/esophagogastric junction adenocarcinoma, reflecting its unique potential to address a rare and serious condition. Clinical trials have demonstrated both positive efficacy and excellent safety profiles for this promising therapy.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
